Study of Clonidine Efficacy for the Treatment of Impulse Control Disorders in Parkinson's Disease:

Parkinson's Disease Clinical Trial

— ID-CLO  

Official title:

Study of Clonidine Efficacy for the Treatment of Impulse Control Disorders in Parkinson's Disease: A Pilot Double Blind Randomized Trial

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT03552068
• Other study ID #: 69HCL18_0135
• Secondary ID: 2019-000165-20
• Status: Completed
• Phase: Phase 2
• Start date: May 15, 2019
• Est. completion date: December 3, 2021

Study information

• Verified date: January 2022
• Source: Hospices Civils de Lyon
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

Noradrenergic system is involved in impulsivity in the general population and is altered in Parkinson's disease (PD) in the early stages of the disease. Thus, targeting this system could be of interest in impulse control disorder (ICD). Acting on the noradrenergic system is possible using clonidine, an α2 adrenergic agonist largely used in hypertension treatment and that induces a decrease of NADR release. Thus, our aim is to conduct a proof of concept study evaluating the efficacy and safety of clonidine on ICD in PD. This study is a multicenter, randomized, double-blind, placebo-controlled in parallel group clinical trial.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 38
• Est. completion date: December 3, 2021
• Est. primary completion date: July 15, 2021
• Accepts healthy volunteers: No
• Gender: All
• Age group: 30 Years to 80 Years

Eligibility

Inclusion Criteria:

• Patients with PD according to MDS (movement disorders society) criteria for at least one year

• Patients with ICD with a QUIP-RS score =10 and/or at least one of the sub-scores in the following range: Pathological gambling between >6 and 12; Pathological gambling between >8 and 12; Hypersexuality between > 8 and 12; Eating between > 7 and 12. The use of "lower" margins will guarantee that patients will present behavioral disturbances severe enough to justify clonidine treatment. On the other hand, the use of "upper" margins will guarantee that the patients included in the trial will not suffer from ICD too severe to ethically participate to a placebo controlled study.

• Weight between 40 and 95kg

• Stable antiparkinsonian medication since at least 2 months before randomization and medication supposed to remain stable during the study

• ICD onset after Parkinson's disease onset and after initiation of dopaminergic drugs

• No signs of dementia (Montreal Cognitive Assessment, MOCA >20);

• No lactose intolerance which may compromise the tolerance of the placebo;

• Patients with health insurance

• Patients without judicial protection measure except directly linked to ICD

• For women of childbearing potential, an effective contraception method for at least 2 months before randomization (as implants or oral oestro-progestative contraceptives), condom use for men during the study. ßHCG dosage in urine should be negative at randomization for women.

Exclusion Criteria:

Patients with major depression (BDI >19);

• Patients with another parkinsonian syndrome (Parkinson "plus" or vascular Parkinsonism)

• Orthostatic hypotension

• Patients with swallowing disorders that may prevent oral medication,

• Contraindication to clonidine: Hypersensibility; Severe bradyarythmia due to a cardiac disease

• Patients receiving a treatment potentially interacting with clonidine

• Patients with Raynaud's disease or obliterating thromboangiitis

• Patients With Heart failure or severe coronary artery disease

• Patients with a drug treatment having a potential interaction with clonidine (see list, appendix 2);

• Presence of renal failure (Cockcroft-Gault at inclusion visit<30 ml/min/1,73m2);

• Patients with a present or past history of addiction (apart ICD) or with a substance abuse (except Tabaco)

• Pregnant or lactating women

• Already participating in another biomedical research project

Related Conditions & MeSH terms

• Disease
• Mpulse Control Disorders
• Parkinson Disease
• Parkinson's Disease

Intervention

Drug:
• placebo
Treatment (placebo) will be taken during 8 weeks with one visit at 2, 4 and 8 weeks. Medication: placebo twice a day (in the morning and evening).
• Clonidine
Treatment will be taken during 8 weeks with one visit at 2, 4 and 8 weeks. Medication: 75 µg of clonidine twice a day (in the morning and evening).

Locations

Country	Name	City	State
France	Hospices Civils de Lyon	Bron

Sponsors (1)

Lead Sponsor	Collaborator
Hospices Civils de Lyon

Country where clinical trial is conducted

France, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	QUIP-RS (Questionnaire for Impulsive-Compulsive Disorders in Parkinson's disease - Rating Scale)	Diminution of impulse control disorder severity on the initial more elevated sub-score of the QUIP-RS between the first visit and the eighth week under clonidine.; Diminution of impulse control disorder severity on the initial more elevated sub-score of the QUIP-RS between the first visit and the eighth week under clonidine.; Diminution of impulse control disorder severity on the initial more elevated sub-score of the QUIP-RS between the first visit and the eighth week under clonidine.	at 8 weeks
Secondary	MDS-UPDRS	The Movement Disorder Society Unified Parkinson Disease Rating	at 4 and 8 weeks
Secondary	STAI	State-Trait Anxiety Index	at 4 and 8 weeks
Secondary	BDI II	Beck Depression Inventory II It is a self-administered questionnaire each of them using a four-point ordinal scoring system. For the summary index the scores were standardized from 1 to 40, so that higher scores indicate higher depression.	at 4 and 8 weeks
Secondary	ECMP scores	Behavior evaluation of Parkinson's patients It is a self-administered questionnaire each of them using a four-point ordinal scoring system. For the summary index the scores were standardized from 1 to 40, so that higher scores indicate higher depression.	at 4 and 8 weeks
Secondary	QUIP-RS sub-scores	Questionnaire for Impulsive-Compulsive Disorders in Parkinson's disease - Rating Scale Diminution of impulse control disorder severity on the initial more elevated sub-score of the QUIP-RS between the first visit and the fourth weeks under clonidine.; It is a self-administered questionnaire. For the summary index the scores were standardized from 1 to 112, so that higher scores indicate higher Impulse control disorder. The sub score are standardized between 0 and 16.	at 4 weeks
Secondary	QUIP-RS total score	Evolution of QUIP-RS total score and sub-scores Diminution of impulse control disorder severity on total score of the QUIP-RS between the first visit, the fourth and the eighth weeks under clonidine.; It is a self-administered questionnaire. For the summary index the scores were standardized from 1 to 112, so that higher scores indicate higher Impulse control disorder.	at 4 and 8 weeks
Secondary	PDQ 39 scale (Parkinson Disease Quotation)	It is a self-administered questionnaire comprised of 39 questions, each of them using a five-point ordinal scoring system, from which a single summary index can be calculated. For the summary index the scores were standardized from 0 to 100, so that higher scores indicate poorer quality of life.	at 4 and 8 weeks